Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canada-based vaccine enhancement company ImmunoVaccine Technologies has signed a binding memorandum of understanding to acquire Immunotope, a Pennsylvania-based biotechnology company.
Subscribe to our email newsletter
The acquisition will bring together ImmunoVaccine Technologies (IVT’s) signature VacciMax platform with Immunotope’s portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. The combined clinical-stage company will continue to support Immunotope’s ongoing Phase I immunotherapeutic vaccine clinical trial in ovarian and breast cancer patients at Duke University Comprehensive Cancer Center.
Randal Chase, president and CEO of IVT, said: “With this acquisition, we enhance our research capabilities, expand our operations into the US and gain a distinct competitive advantage for our immunotherapy products.”